1-Aminobenzotriazole, a Known Cytochrome P450 Inhibitor, Is a Substrate and Inhibitor of N-Acetyltransferase
Authors:
- Q. SunQSQ. Sun
- T. W. HarperTHT. W. Harper
- E. A. DierksEDE. A. Dierks
- L. ZhangLZL. Zhang
- S. ChangSCS. Chang
- A. D. RodriguesARA. D. Rodrigues
- P. MarathePMP. Marathe
- 1 September 2011
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 39 (9) , 1674-1679
Abstract
1-Aminobenzotriazole (ABT) has been used widely as a nonselective in vitro and in vivo inhibitor of cytochrome P450 enzymes. To date, however, it has not been evaluated as an inhibitor of UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), and N-acetyltransferase (NAT). In the present study, ABT was shown not to inhibit UGT and SULT activity (acetaminophen and 7-hydroxycoumarin as substrates) in rat liver microsomes and rat liver 9000g supernatant fraction (RLS9), respectively. However, it did inhibit the RLS9-catalyzed N-acetylation of procainamide (IC50 ∼ 30 μM), and no preincubation time dependence was evident. In agreement, oral ABT (100 mg/kg, 2 h predose) decreased the clearance of intravenous procainamide (45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio in urine (0.74 versus 0.21) and plasma (area under the curve ratio 0.59 versus 0.11). Additional studies with human forms of NAT (hNAT1 and hNAT2) revealed that ABT is a more potent inhibitor of hNAT2 compared with hNAT1 (IC50 158 μM versus > 1 mM). Consistent with the IC50 estimate, formal inhibition studies revealed that inhibition of hNAT2 was competitive with an inhibition constant of 67 μM. In accordance with the competitive inhibition, ABT was shown to undergo N-acetylation in the presence of both human NAT forms, with hNAT1 exhibiting less activity under the same assay conditions (∼40% of hNAT2). In summary, the results described herein indicate that ABT is a substrate and inhibitor of NAT. Such an interaction should be considered when using ABT as a nonselective inhibitor of P450, especially when NAT-dependent metabolism is also involved.Keywords
This publication has 28 references indexed in Scilit:
- Utility of the carboxylesterase inhibitorbis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptorXenobiotica, 2010
- Quantitative Tissue and Gene-Specific Differences and Developmental Changes in Nat1, Nat2, and Nat3 mRNA Expression in the RatDrug Metabolism and Disposition, 2008
- The Use of 1-Aminobenzotriazole in Differentiating the Role of CYPMediated First Pass Metabolism and Absorption in Limiting Drug Oral Bioavailability: A Case StudyDrug Metabolism Letters, 2008
- EXTRAHEPATIC METABOLISM OF CARBAMATE AND ORGANOPHOSPHATE THIOETHER COMPOUNDS BY THE FLAVIN-CONTAINING MONOOXYGENASE AND CYTOCHROME P450 SYSTEMSDrug Metabolism and Disposition, 2005
- EFFECTIVE DOSING REGIMEN OF 1-AMINOBENZOTRIAZOLE FOR INHIBITION OF ANTIPYRINE CLEARANCE IN GUINEA PIGS AND MICE USING SERIAL SAMPLINGDrug Metabolism and Disposition, 2004
- Identification of Metabolic Pathways Involved in the Biotransformation of Tolperisone by Human Microsomal EnzymesDrug Metabolism and Disposition, 2003
- Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and MonkeysDrug Metabolism and Disposition, 2002
- Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2Biochemical Journal, 2000
- A convenient radiometric assay for flavin-containing monooxygenase activityAnalytical Biochemistry, 1987
- Paracetamol Metabolism in the Rat: Relationship to Covalent Binding and Hepatic DamageXenobiotica, 1976